Replies to post #38193 on Biotech Values

[Biowatch]

Re: Obvious patent standards

This is going to be a big deal.

Addressed in #msg-15060518
"Businesses Split on Patent Case
Friday November 24, 8:29 pm ET
By Christopher S. Rugaber, AP Business Writer
Companies Differ on How Supreme Court Should Decide Gas-Pedal Patent Case

...But Johnson & Johnson, GE and DuPont, have filed their own brief arguing that major changes to the patent system would jeopardize billions of dollars invested in product innovation. They want to protect pharmaceutical and chemical products from generic manufacturers and counterfeiters, attorneys involved in the case said..."

It somewhat relates to:
#msg-15097330
>>...the agency does face a growing backlog across all areas.

"We have 700,000 applications in the pipeline," Kisliuk said. "Some are for nanotech, some not. This backlog isn't unique to nanotech."

Last year, the office issued fewer patents than usual because of an initiative to improve patent quality, Kisliuk said.<<